JP2016516774A - 光応答性化合物 - Google Patents

光応答性化合物 Download PDF

Info

Publication number
JP2016516774A
JP2016516774A JP2016507609A JP2016507609A JP2016516774A JP 2016516774 A JP2016516774 A JP 2016516774A JP 2016507609 A JP2016507609 A JP 2016507609A JP 2016507609 A JP2016507609 A JP 2016507609A JP 2016516774 A JP2016516774 A JP 2016516774A
Authority
JP
Japan
Prior art keywords
cbl
compound
light
cells
cobalamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016507609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516774A5 (enExample
Inventor
エル． ローレンス，デヴィッド
エル． ローレンス，デヴィッド
シェル，トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2016516774A publication Critical patent/JP2016516774A/ja
Publication of JP2016516774A5 publication Critical patent/JP2016516774A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/06—Cobalt compounds
    • C07F15/065—Cobalt compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016507609A 2013-04-08 2014-04-08 光応答性化合物 Withdrawn JP2016516774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809695P 2013-04-08 2013-04-08
US61/809,695 2013-04-08
PCT/US2014/033337 WO2014168950A1 (en) 2013-04-08 2014-04-08 Photo-responsive compounds

Publications (2)

Publication Number Publication Date
JP2016516774A true JP2016516774A (ja) 2016-06-09
JP2016516774A5 JP2016516774A5 (enExample) 2017-06-01

Family

ID=51689955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507609A Withdrawn JP2016516774A (ja) 2013-04-08 2014-04-08 光応答性化合物

Country Status (5)

Country Link
US (1) US20160144031A1 (enExample)
EP (1) EP2983677A4 (enExample)
JP (1) JP2016516774A (enExample)
CN (1) CN105307663A (enExample)
WO (1) WO2014168950A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
CA2954463C (en) 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
CN121270700A (zh) 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
US20220062418A1 (en) * 2018-11-29 2022-03-03 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
US20220259272A1 (en) * 2019-06-14 2022-08-18 The University Of North Carolina At Chapel Hill Photoactive compositions for therapuetic agent delivery
CN110215179B (zh) * 2019-06-20 2022-02-25 京东方科技集团股份有限公司 胶囊内窥镜的释药装置及胶囊内窥镜
CN112168977A (zh) * 2020-10-27 2021-01-05 西南大学 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用
CN114216982B (zh) * 2021-12-14 2024-08-09 黑龙江飞鹤乳业有限公司 维生素b12的检测方法
WO2026030557A1 (en) * 2024-07-31 2026-02-05 The University Of North Carolina At Chapel Hill Compositions and methods for tissue protection and therapuetic agent delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264592C (en) * 1996-08-27 2012-02-21 University Of Utah Research Foundation Bioconjugates and delivery of bioactive agents
WO2004037983A2 (en) * 2002-10-24 2004-05-06 Albert Einstein College Of Medicine Of Yeshiva University Caged ligands and uses thereof
EP1565714A4 (en) * 2002-11-18 2009-06-03 Panomics Inc ORDERING uncaging
CA2505603A1 (en) * 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
WO2004062475A2 (en) * 2003-01-10 2004-07-29 Albert Einstein College Of Medicine Of Yeshiva University Fluorescent assays for protein kinases
US9744236B2 (en) * 2009-06-26 2017-08-29 The Trustees Of Columbia University In The City Of New York Photolabile compounds

Also Published As

Publication number Publication date
CN105307663A (zh) 2016-02-03
US20160144031A1 (en) 2016-05-26
WO2014168950A1 (en) 2014-10-16
EP2983677A4 (en) 2016-11-16
EP2983677A1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
US20160144031A1 (en) Photo-Responsive Compounds
Deng et al. Natural-killer-cell-inspired nanorobots with aggregation-induced emission characteristics for near-infrared-II fluorescence-guided glioma theranostics
Kim et al. Biomedical applications of copper-free click chemistry: in vitro, in vivo, and ex vivo
Zhang et al. Inflammation-responsive nanoagents for activatable photoacoustic molecular imaging and tandem therapies in rheumatoid arthritis
Wang et al. Integrating enzymatic self-assembly and mitochondria targeting for selectively killing cancer cells without acquired drug resistance
Qiu et al. Glutathione-sensitive hyaluronic acid-mercaptopurine prodrug linked via carbonyl vinyl sulfide: a robust and CD44-targeted nanomedicine for leukemia
Spillmann et al. Multifunctional liquid crystal nanoparticles for intracellular fluorescent imaging and drug delivery
Chen et al. Copper-coordination driven brain-targeting nanoassembly for efficient glioblastoma multiforme immunotherapy by cuproptosis-mediated tumor immune microenvironment reprogramming
CN108578708A (zh) 一种双靶向多肽-药物偶联物及其制备方法与抗肿瘤应用
Li et al. Bio-orthogonal supramolecular latching inside live animals and its application for in vivo cancer imaging
Snell et al. Cell-derived vesicles for in vitro and in vivo targeted therapeutic delivery
Sampedro et al. Cell uptake and localization studies of squaramide based fluorescent probes
US8900551B2 (en) Peptide which passes through blood-brain barrier and targets apoptosis of neurodegenerative brain disease site and uses thereof
Yao et al. Synthesis and cytotoxic study of a platinum (IV) anticancer prodrug with selectivity toward luteinizing hormone-releasing hormone (LHRH) receptor-positive cancer cells
Bhattacharya et al. Water-soluble blue fluorescent nonconjugated polymer dots from hyaluronic acid and hydrophobic amino acids
Nasrolahi Shirazi et al. Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters
Zheng et al. Silicon (IV) phthalocyanines substituted axially with different nucleoside moieties. Effects of nucleoside type on the photosensitizing efficiencies and in vitro photodynamic activities
Nakajima et al. Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy
Ma et al. Intracellular delivery and deep tissue penetration of nucleoside triphosphates using photocleavable covalently bound dendritic polycations
Ye et al. Self-reinforced cancer targeting (SRCT) depending on reciprocally enhancing feedback between targeting and therapy
CA2963218C (en) Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
Wang et al. Boosting the theranostic effect of liposomal probes toward prominin-1 through optimized dual-site targeting
Feng et al. Multi-Armed Anti-CD40-Mediated dual drug delivery system based on mesoporous silica/au Nanorod nanocomposites for multimodality imaging and combination therapy
WO2019208820A1 (ja) 細胞内物質移送システムおよびその利用
Vettorato et al. Development and validation of novel Z-360-based macromolecules for the active targeting of CCK2-R

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170410

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180301